Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announce...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announce...
Source route
Continue on investors.abeonatherapeutics.com
Leave the platform to read the original full article on the publisher site.
Source: Abeona Therapeutics
Scope: Industry
Related coverage
More related coverage
Menicon Renames Its Sales Subsidiaries in Malaysia and Indonesia – Promoting Brand Integration and Business Expansion in Southeast Asia –
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
La FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o agua
SwiftPharma Expands R&D Footprint to Leuven in Strategic Co-Location with Benno Therapeutics
A dynamic, member-driven organisation dedicated to fostering innovation and growth in the life scien...